Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain
Lynn R. Webster(Adherent Technologies (United States)), Eric Carter(Research Triangle Park Foundation), Ben Lasko(Manna Research), Bart Morlion(KU Leuven), Eric Mortensen(Regeneron (United States)), C. Kleoudis(Research Triangle Park Foundation), Jan Peter Jansen, Amy Pierce(Research Triangle Park Foundation), John F. Peppin, Gordon Irving(Swedish Medical Center), Jerry Snidow(Research Triangle Park Foundation)
Cited by 144
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309